Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
Clinical outcomes of chemotherapy for patients with advanced pancreatic adenocarcinoma in a real-world setting might differ from outcomes in randomized clinical trials (RCTs). Here we show in a single-institution cohort of 595 patients that median overall survival (OS) of patients who received gemci...
Main Authors: | Maximilian Kordes, Jingru Yu, Oscar Malgerud, Maria Gustafsson Liljefors, J. -Matthias Löhr |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/9/1326 |
Similar Items
-
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
by: Sara Pusceddu, et al.
Published: (2019-04-01) -
Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
by: Takafumi Mie, et al.
Published: (2023-01-01) -
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
by: Alberto Servetto, et al.
Published: (2021-09-01) -
Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer
by: Hayato Muranaka, et al.
Published: (2023-06-01) -
Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
by: Aurélien Lambert, et al.
Published: (2021-09-01)